HealthEquity (HQY)
(Delayed Data from NSDQ)
$78.91 USD
-1.39 (-1.73%)
Updated Apr 30, 2024 04:00 PM ET
After-Market: $78.91 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$78.91 USD
-1.39 (-1.73%)
Updated Apr 30, 2024 04:00 PM ET
After-Market: $78.91 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth A Momentum B VGM
Zacks News
Is Gilead Sciences (GILD) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Gilead Sciences (GILD) and HealthEquity (HQY) have performed compared to their sector so far this year.
PINC vs. HQY: Which Stock Is the Better Value Option?
by Zacks Equity Research
PINC vs. HQY: Which Stock Is the Better Value Option?
Harpoon Therapeutics, Inc. (HARP) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Harpoon Therapeutics, Inc. (HARP) delivered earnings and revenue surprises of 41.67% and 73.11%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Homology Medicines (FIXX) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Homology Medicines (FIXX) delivered earnings and revenue surprises of -25.53% and 23.62%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
PINC or HQY: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
PINC vs. HQY: Which Stock Is the Better Value Option?
Is G1 Therapeutics (GTHX) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how G1 Therapeutics (GTHX) and HealthEquity (HQY) have performed compared to their sector so far this year.
PINC vs. HQY: Which Stock Is the Better Value Option?
by Zacks Equity Research
PINC vs. HQY: Which Stock Is the Better Value Option?
HealthEquity (HQY) Moves 5.3% Higher: Will This Strength Last?
by Zacks Equity Research
HealthEquity (HQY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Is G1 Therapeutics (GTHX) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how G1 Therapeutics (GTHX) and HealthEquity (HQY) have performed compared to their sector so far this year.
Zacks Industry Outlook Highlights HealthEquity, AMN Healthcare and ModivCare
by Zacks Equity Research
HealthEquity, AMN Healthcare and ModivCare have been highlighted in this Industry Outlook article.
3 Medical Services Stocks Braving Near-Term Industry Headwinds
by Urmimala Biswas
The Zacks Medical - Services industry is growing on digital healthcare adoption. HQY, AMN and MODV are set to gain the most. However, staffing shortages may disrupt the trend.
HealthEquity (HQY) Q2 Earnings Lag Estimates, Margins Down
by Zacks Equity Research
HealthEquity (HQY) witnesses solid growth in HSAs, besides recording robust performances in majority of its segments, in the second quarter of fiscal 2023.
HealthEquity (HQY) Misses Q2 Earnings Estimates
by Zacks Equity Research
HealthEquity (HQY) delivered earnings and revenue surprises of -2.94% and 1.35%, respectively, for the quarter ended July 2022. Do the numbers hold clues to what lies ahead for the stock?
HealthEquity (HQY) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
HealthEquity (HQY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Premier, Inc. (PINC) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Premier, Inc. (PINC) delivered earnings and revenue surprises of 1.67% and 1.61%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
XpresSpa Group, Inc. (XSPA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
XpresSpa Group, Inc. (XSPA) delivered earnings and revenue surprises of 20% and 1.24%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Onconova Therapeutics, Inc. (ONTX) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Onconova Therapeutics, Inc. (ONTX) delivered earnings and revenue surprises of 5% and 5%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
ICLR vs. HQY: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ICLR vs. HQY: Which Stock Is the Better Value Option?
Has Elevance Health, Inc. (ELV) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Elevance Health (ELV) and HealthEquity (HQY) have performed compared to their sector so far this year.
What's in Store for West Pharmaceutical (WST) in Q2 Earnings?
by Zacks Equity Research
West Pharmaceutical's (WST) second-quarter results are likely to reflect strength in the Proprietary Products business.
Ecolab (ECL) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Ecolab's (ECL) second-quarter results are likely to reflect continued strength in its Global Industrial segment.
Stryker (SYK) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Stryker's (SYK) second-quarter results are likely to reflect strong segmental performances. However, the resurgence of COVID-19 infections is likely to have hurt sales growth.
Has HealthEquity (HQY) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how HealthEquity (HQY) and Intra-Cellular Therapies (ITCI) have performed compared to their sector so far this year.
Why Is HealthEquity (HQY) Down 10% Since Last Earnings Report?
by Zacks Equity Research
HealthEquity (HQY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why HealthEquity (HQY) is Poised for a Turnaround After Losing 7.7% in 4 Weeks
by Zacks Equity Research
HealthEquity (HQY) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.